Latest Erlotinib Stories
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when.
Almost twelve million -- that’s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It’s a problem researchers at Case Western Reserve University are working to better understand.
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.
- Withering but not falling off, as a blossom that persists on a twig after flowering.